uPath PD-L1 (SP263) Image Analysis, NSCLC

Roche uPath Enterprise Software

Ready-to-use, fast, consistent and automated algorithm
An intelligent and advanced digital pathology solution requires artificial intelligence-based image analysis tools that empower pathologists to confidently and objectively assess whole tissue slide images.

Compare
Category: Tag:

Product Description

uPath PD-L1 (SP263) image analysis, NSCLC*

The uPath PD-L1 (SP263) image analysis, NSCLC algorithm is an adjunctive computer-assisted tool that identifies PD-L1 positive and negative tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded Non-small cell lung cancer (NSCLC) tissue.

*CE-IVD marked. For Research Use Only in the US. Not for use in diagnostic procedures in the US.

A robust and reliable solution for enhanced image analysis

Integrated and ready-to-use

Validated for use with the VENTANA PD-L1 (SP263) assay and Roche uPath enterprise software.

Quick and automated

Pathologist-trained image analysis algorithm quickly calculates PD-L1 tumor cell positivity.

Accurate, consistent and confident

Actionable assessment of slide images that are objective and reproducible.

Enhancing your pathology workflow

  • Enhanced accuracy with a Pathologist-trained image analysis algorithm which results in objective and reproducible scoring of slide images scanned on VENTANA DP 200 or VENTANA DP 600 slide scanner and stained with the VENTANA PD-L1 (SP263) Assay
  • Fully embedded into the  Roche uPath enterprise software to enable seamless viewing, aligning, syncing, sharing, and reporting
  • Speed up time to results for user-defined regions of interest with whole slide analysis (WSA) and automated pre-computing of the slide image prior to pathologist assessment
  • Quickly calculate PD-L1 tumor cell positivity
  • A clear visual overlay highlights tumor cells with and without membranous staining for easy reference

Registration Status

*CE-IVD marked. For Research Use Only in the US. Not for use in diagnostic procedures in the US.

Refer to the product-specific labeling for the regulatory status of the scanner and uPath. When Research Use Only products are used with IVD products, the integrated workflow will be for Research Use Only and cannot be used for diagnostic procedures.

More Solutions from Roche

Additional Information

Clinical | Research Suitability

Clinical

Imaging Modality Supported

Brightfield

User Customizable | Application-Specific Algorithms

Application Specific

Max No. Multiplexed Biomarkers

>50 Biomarkers, Algorithm only certified for use on the Roche VENTANA PD-L1 (SP263) Assay stained on a BENCHMARK Ultra

Supported Assay Types

Immunohistochemistry (IHC)

On-Premise Deployment

yes

Cloud Deployment

yes

TMA Support

no

File Formats Produced | Supported

Ventana .bif

Note

The uPath PD-L1 (SP263) image analysis, NSCLC algorithm is an adjunctive computer-assisted tool that identifies PD-L1 positive and negative tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded Non-small cell lung cancer (NSCLC) tissue. The algorithms uses a Whole Slide Analysis approach. When a slide is scanned on a VENTANA scanner, and sent across to uPath, it automatically triggers the image to be analysed across the entire section, meaning that when it comes time to review the slide in uPath, all the heavy computational work has already taken place, and the retrieval of this information for any given region of interest happens almost instantaneously. Meaning a pathologist is never left waiting for an algorithm to run before they can continue reporting a case.

Clicking on the reviews will open them into a new webpage where you can see a detailed review, including individual scores for ease-of-use, reliability, value-for-money and service and support criteria.



There are no reviews yet.

You may also like
  • VENTANA DP 600 Slide Scanner

    Read more Compare
  • VENTANA DP 200 Slide Scanner

    Read more Compare